Detection of human papillomavirus

An in vitro method of detecting human papillomavirus nucleic acid in a sample, comprising:

• contacting said sample with forward and reverse oligonucleotide primers, wherein said primers bind to target sites in the human papillomavirus L1 gene, or the complement thereof, under conditions suitable to promote amplification of a portion of said human papillomavirus L1 gene or complement, thereby generating an amplicon;
• contacting said amplicon with a probe, wherein the probe binds to a target site within said amplicon;
• and
• detecting binding of said probes to said amplicon;
• wherein the probe comprises a nucleic acid sequence having at least 85%, preferably at least 90%, preferably at least 95%, most preferably 100% sequence identity to a nucleic acid sequence selected from SEQ ID NO:
• 15, SEQ ID NO:
• 16, SEQ ID NO:
• 17, SEQ ID NO:
• 18, SEQ ID NO:
• 19, SEQ ID NO:
• 20, SEQ ID NO:
• 21, SEQ ID NO:
• 22, SEQ ID NO:
• 23, SEQ ID NO:
• 24, SEQ ID NO:
• 25, SEQ ID NO:
• 26, SEQ ID NO:
• 27, SEQ ID NO:
• 28, SEQ ID NO:
• 29, SEQ ID NO:
• 30, SEQ ID NO:
• 31, SEQ ID NO:
• 32, SEQ ID NO:
• 33 and SEQ ID NO:
• 34.

An in vitro method of detecting human papillomavirus nucleic acid in a sample, comprising:

• contacting said sample with at least one oligonucleotide probe, wherein the probe binds a target site within the human papillomavirus L1 gene, or the complement thereof;
• and
• detecting binding of said probe to said target site;
• wherein said probe comprises a nucleic acid sequence having at least 85%, preferably at least 90%, preferably at least 95%, most preferably 100% sequence identity to a nucleic acid sequence selected from SEQ ID NO:
• 15, SEQ ID NO:
• 16, SEQ ID NO:
• 17, SEQ ID NO:
• 18, SEQ ID NO:
• 19, SEQ ID NO:
• 20, SEQ ID NO:
• 21, SEQ ID NO:
• 22, SEQ ID NO:
• 23, SEQ ID NO:
• 24, SEQ ID NO:
• 25, SEQ ID NO:
• 26, SEQ ID NO:
• 27, SEQ ID NO:
• 28, SEQ ID NO:
• 29, SEQ ID NO:
• 30, SEQ ID NO:
• 31, SEQ ID NO:
• 32, SEQ ID NO:
• 33 and SEQ ID NO:
• 34.

A probe, wherein said probe binds to a target sequence within the human papillomavirus L1 gene, or the complement thereof;

• wherein said probe comprises a nucleic acid sequence selected from the group consisting of:
• (i) a nucleic acid sequence having at least 85%, preferably at least 90%, preferably at least 95%, most preferably 100% sequence identity to a nucleic acid sequence selected from SEQ ID NO:
• 16, SEQ ID NO:
• 18, SEQ ID NO:
• 19, SEQ ID NO:
• 20, SEQ ID NO:
• 21, SEQ ID NO:
• 22, SEQ ID NO:
• 23, SEQ ID NO:
• 24, SEQ ID NO:
• 25, SEQ ID NO:
• 26, SEQ ID NO:
• 27, SEQ ID NO:
• 28, SEQ ID NO:
• 29, SEQ ID NO:
• 30, SEQ ID NO:
• 31, SEQ ID NO:
• 32, SEQ ID NO:
• 33 and SEQ ID NO:
• 34;
• or
• (ii) a nucleic acid sequence having at least 96% sequence identity to the nucleic acid sequence of SEQ ID NO:15;
• or wherein said probe consists of the nucleic acid sequence of SEQ ID NO:
• 17.

A set of at least two different probes, wherein said probes bind to target sites in the human papillomavirus L1 gene, or the complement thereof, and wherein each of said probes comprises a different nucleic acid sequence selected from:

• (a) a nucleic acid sequence having at least 85%, preferably at least 90%, preferably at least 95%, most preferably 100% sequence identity to SEQ ID NO:
• 15;
• (b) a nucleic acid sequence having at least 85%, preferably at least 90%, preferably at least 95%, most preferably 100% sequence identity to SEQ ID NO:
• 16;
• (c) a nucleic acid sequence having at least 85%, preferably at least 90%, preferably at least 95%, most preferably 100% sequence identity to SEQ ID NO:
• 17;
• (d) a nucleic acid sequence having at least 85%, preferably at least 90%, preferably at least 95%, most preferably 100% sequence identity to SEQ ID NO:
• 18;
• (e) a nucleic acid sequence having at least 85%, preferably at least 90%, preferably at least 95%, most preferably 100% sequence identity to SEQ ID NO:
• 19;
• (f) a nucleic acid sequence having at least 85%, preferably at least 90%, preferably at least 95%, most preferably 100% sequence identity to SEQ ID NO:
• 20;
• (g) a nucleic acid sequence having at least 85%, preferably at least 90%, preferably at least 95%, most preferably 100% sequence identity to SEQ ID NO:
• 21;
• (h) a nucleic acid sequence having at least 85%, preferably at least 90%, preferably at least 95%, most preferably 100% sequence identity to SEQ ID NO:
• 22;
• (i) a nucleic acid sequence having at least 85%, preferably at least 90%, preferably at least 95%, most preferably 100% sequence identity to SEQ ID NO:
• 23;
• (j) a nucleic acid sequence having at least 85%, preferably at least 90%, preferably at least 95%, most preferably 100% sequence identity to SEQ ID NO:
• 24;
• (k) a nucleic acid sequence having at least 85%, preferably at least 90%, preferably at least 95%, most preferably 100% sequence identity to SEQ ID NO:
• 25;
• (l) a nucleic acid sequence having at least 85%, preferably at least 90%, preferably at least 95%, most preferably 100% sequence identity to SEQ ID NO:
• 26;
• (m) a nucleic acid sequence having at least 85%, preferably at least 90%, preferably at least 95%, most preferably 100% sequence identity to SEQ ID NO:
• 27;
• (n) a nucleic acid sequence having at least 85%, preferably at least 90%, preferably at least 95%, most preferably 100% sequence identity to SEQ ID NO:
• 28;
• (o) a nucleic acid sequence having at least 85%, preferably at least 90%, preferably at least 95%, most preferably 100% sequence identity to SEQ ID NO:
• 29;
• (p) a nucleic acid sequence having at least 85%, preferably at least 90%, preferably at least 95%, most preferably 100% sequence identity to SEQ ID NO:
• 30;
• (q) a nucleic acid sequence having at least 85%, preferably at least 90%, preferably at least 95%, most preferably 100% sequence identity to SEQ ID NO:
• 31;
• (r) a nucleic acid sequence having at least 85%, preferably at least 90%, preferably at least 95%, most preferably 100% sequence identity to SEQ ID NO:
• 32;
• (s) a nucleic acid sequence having at least 85%, preferably at least 90%, preferably at least 95%, most preferably 100% sequence identity to SEQ ID NO:
• 33;
• and
• (t) a nucleic acid sequence having at least 85%, preferably at least 90%, preferably at least 95%, most preferably 100% sequence identity to SEQ ID NO:
• 34.